P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC)

Autor: Salani, F., Guerri, V., Cesario, S., Sammuri, P., Genovesi, V., Pratesi, F., Massa, V., Catanese, S., Vivaldi, C., Fornaro, L., Crea, F., Migliorini, P., Galimberti, S., Masi, G.
Zdroj: In Annals of Oncology June 2023 34 Supplement 1:S32-S32
Databáze: ScienceDirect